Treating depression with ketamine: We need incremental treatment for depression
Recently, the Food and Drug Administration approved a nasal spray version of the drug Ketamine, named Spravato (esketamine), for use as a supplement to oral antidepressants taken by adults living with treatment-resistant depression.
The announcement was accompanied by a flurry of media excitement as Spravato is the first medication for depression with a new mechanism of action since Prozac (fluoxetine hydrochloride) was approved in the late 1980s.
The risks …
Treating depression with ketamine: We need incremental treatment for depression








![Politics and fear have replaced science in U.S. pain management [PODCAST]](https://kevinmd.com/wp-content/uploads/11c2db8f-2b20-4a4d-81cc-083ae0f47d6e-190x100.jpeg)


![Why physicians pay more in taxes and how to reclaim your income [PODCAST]](https://kevinmd.com/wp-content/uploads/65a06f47-06d1-44f6-b074-deb9a2d19a25-190x100.jpeg)




